Antiarrhythmic drugs

127
HEART ashfaq

Transcript of Antiarrhythmic drugs

Page 1: Antiarrhythmic drugs

HEART

ashfaq

Page 2: Antiarrhythmic drugs

Pumping blood

Details??

Cardiac Function

Page 3: Antiarrhythmic drugs

Rate & Rhythm

Contraction

Page 4: Antiarrhythmic drugs

Contraction

•Chambers ( coordination)

Recall

Page 5: Antiarrhythmic drugs

• Contraction with

– Rhythm & Rate

– Coordinated• (alternate Contraction (systole) & (Diastole)

How comes ???

Page 6: Antiarrhythmic drugs

Specialsed Conducting System

Page 7: Antiarrhythmic drugs

The Conducting System of the Heart

Page 8: Antiarrhythmic drugs
Page 9: Antiarrhythmic drugs

DISTINGUISHED FEATURES OF CARDIAC MUSCLE FROM OTHER EXCITABLE TISSUE

Pacemaker Activity (automaticity) Absence of fast Na+ current in SA & AV node Ca++ current initiates action potential. Long action potential (Plateau) & Refractory

period Influx of Ca+ during Plateau

Page 10: Antiarrhythmic drugs

Normal Cardiac Rhythm

Page 11: Antiarrhythmic drugs

Parts of a Normal Typical ECG

0.1- 0.22

< 0.12

< 0.10

0.44 – 0.46

Page 12: Antiarrhythmic drugs

Ionic Basis of

Membrane Electrical Activity

Page 13: Antiarrhythmic drugs

During Cardiac Cycle: Ions ( Na+, K+, Ca+ & Cl- ) moves across cell membranes in response to their concentration gradients only when their channels open. Ionic movement produces currents responsible for the cardiac action potential.

Page 14: Antiarrhythmic drugs

Diastolicchannelcurrents

Inward Na+ Current

Page 15: Antiarrhythmic drugs

m (activation) gate: their opening for Na+ ions leads to depolarization from threshold to action potential voltage.h (inactvation) gate: closure occurs after this brief opening of m gates

Page 16: Antiarrhythmic drugs

- 85

influx

eflux

Absolute Refractory Period

Relative R.P.

E after depolarizationD

Threshold

Phase 0: Depolarization; Rapid Sodium Influx;Resting voltage has become positive.

Phase 1:Early Repolarization; brief K+ & Cl- eflux

Phase 2:Plateu phase; Ca++ influx

Phase 3:Rapid repolarization; K+ & Cl- eflux

Phase 4 ( automaticity ): Ratio of Na+/K+ permeability; cellularelectrolyte balance is slowly restored. Slow Diastolic Depolarization;Until the threshold potential is reached.

Early & Delayed - after depolarization may occur during relative refractory periodbefore the phase 4, due to myocardial damage, so leading to arrhythmias.

Early & Delayed depolarizations interrupt Phase 3

Page 17: Antiarrhythmic drugs

T-type Ca++ opens

K+ closedNa+ unchanged

L-typeCa++

K+ opens

Page 18: Antiarrhythmic drugs

Myocardial Action Potential

I b = background inward sodium current,

If = ‘funny current’,

I cat= transient or ‘T’ type calcium current, opening of channels leads to threshold

I cal = slow responding ‘ L’ type calcium channels,

I k = delayed rectifier potassium current,

Threshold

Ical

Slow Responding Fibers; Ca++ role; as at -55 mV Na+ channels close

SA Node & AV Node or Damaged fibers

Page 19: Antiarrhythmic drugs

I k1= inward rectifier current,

I Na= Fast responding inward sodium current, ( Na channels closes at -55 to -70 mv at which however Ca channel opens ) so in ischemic damage, fast responding fibers are changed into slow responding fibers

I to = transient outward potassium current,

I cal = ‘L’ type calcium channel,

I k = delayed rectifier potassium current,

Upstroke

-85 resting potential

O -

Fast Responding Fibers; Na+ Role

Page 20: Antiarrhythmic drugs

the only conduction pathway

Body Surface Manifestations of the Depolarization and

Repolarization Waves of the heart.

The only conduction pathway

delay of 0.15 sec.

at

to allow blood

to enter from atria to Ventricles

AV node

Page 21: Antiarrhythmic drugs

Normal Sinus Rhythm P waves preceding each QRS complex

Page 22: Antiarrhythmic drugs

Normal

12 leads

Electrocardiogram

Page 23: Antiarrhythmic drugs

The Main Factors affecting Heart Rate

Gender

ANS activity ( Sympathetic/Parasympathetic)

Age

Circulating Hormones ( Adrenaline, Thyroxin)

Physical Activity

Temperature

Baroreceptors Reflex

Emotional States

Page 24: Antiarrhythmic drugs

Arryhthmia

Dysrhythmia

Page 25: Antiarrhythmic drugs

Cardiac Arrhythmia is an abnormality in:

Rate, Rhythm, Site of origin & the conduction of cardiac impulse.

Page 26: Antiarrhythmic drugs

Arrhythmias occur in:

Myocardial Infarction ( >80% )

Anesthetized Patients ( Up To 50% )

Digitalized Patients ( Up To 25% )

(All Antiarrythmics are Arrhythmogenic )

Page 27: Antiarrhythmic drugs

Arrhythmias are caused by:• abnormal pacemaker activity or • abnormal impulse propagation & conduction

• Shift of pacemaker function from SA to other part of the Heart

• Block transmission in the Heart• Abnormal pathway in the heart• Spontaneous generation of Impulses in the heart

There is a normal relationship between “refractory period and conduction velocity”.

Any change in this relationship may lead to arrhythmias

Page 28: Antiarrhythmic drugs

Factors Affecting Rhythm:

Automaticity,

Conduction & its Velocity,

Excitability,

Responsiveness,

Refractoriness & ERP.

Page 29: Antiarrhythmic drugs

Factors Precipitating Arrhythmias

1. Ischemia: Myocardial Infarction, Coronary Vessels Disease,2. Hypoxia : Chronic Cor-pulmonale, Shock, Severe Anemia, 3. Acidosis : Pneumonia, Ketoacidosis, Lactic Acodosis,4. Alkalosis: Respiratory, Metabolic ( K+/Cl- Depletion ), 5. Electrolyte Abnormalities: Hypokalemia, Hypocalcemia,6. Excessive Catecholamines: Sympathetic Stimulation,

Exercise, Hypertension, Thyrotoxicosis, Pheochromocytoma,7. Autonomic Influences: Vasovagal Induced and

Postprandial Arrhythmias, Caffeine, Smoking, Recreational Drug Use, Alcohol Abuse,8. Drug Toxicities: Digoxin, Amiodarone, Β – Blockers,9. Diseases of Cardiac Fibers: Cardiomyopathy, Fibrosis of

His Purkinje System, Post - Cardiac Surgery,

Page 30: Antiarrhythmic drugs

Mechanism of Arrhythmias

Page 31: Antiarrhythmic drugs

• A). Disturbances of Impulse Formation:

1. Changes in Automaticity:

2. Triggered Activity:

• B). Disturbances of Impulse Conduction;

1. Abnormal Regulation of the Heart Beat by

sympathetic, vagal activity or re-entry

• C). Molecular & Genetic Basis of Arrhythmias

Page 32: Antiarrhythmic drugs

A). Disturbances of Impulse Formation:

a). Increase or decrease in pacemaker rate: due to increased or decreased depolarization of Pace Maker Cells;

slope 4: if decreased i.e., more negative leads to slow normal

pace maker rate,

e.g., Vagal discharge, β-receptor Blockers

b). Latent Pace Makers: ( Some Purkinje Fibers; Quiescent Atrial & Ventricular Cells )

they show normally slow phase 4 depolarization and are more prone to acceleration thus may show repetitive pace maker activity esp. in hypokalemia

D

1. Changes in Automaticity:

Page 33: Antiarrhythmic drugs

a). Afterdepolarizations: EADs, DADs ( early or delayed after depolarization )

2. Triggered Activity:

Page 34: Antiarrhythmic drugs

Early After Depolarization's: are usually produced & exacerbated at slow heart rates and

contribute to the development of long QT – related arrhythmias.

Delayed After Depolarization's: occur when intracellular calcium is increased and are exacerbated by

fast heart rates and usually responsible for arrhythmias related to digitalis / catecholamine & to myocardial ischemia

Page 35: Antiarrhythmic drugs

a. Increased slope of phase 4 depolarization as in hypokalemia, β stimulation, etc. leads to early completion of diastolic depolarization, ↑Pace Making

b. Reduced Threshold Potential --- early completion of diastolic depolarization.

“Triggered Activity”: stimulating during relative refractory period so getting action potential earlier than normal.E. Early after depolarization, arises almost from the plateau.D. Delayed after depolarization, arises from the resting potential.

a b

accelerated automaticity e.g.,in sympathetic stimulation

Threshold

Normal or Reduced

Pace Maker Depolarization=Durations of Action Potential & Diastolic Interval )

Page 36: Antiarrhythmic drugs

Four Basic Mechanisms CAUSING Disturbed rhythm

• Delayed after Depolarization• Re-Entry• Ectopic pace maker• Heart Block

Page 37: Antiarrhythmic drugs

B). Disturbances of Impulse Conduction;Abnormal Regulation of the Heart Beat

1). In A / B: Effects of sympathetic stimulation & Nor epinephrine.

Sympathetic stimulation increases the heart rate by increasing the slope of the pacemaker potential

Page 38: Antiarrhythmic drugs

2). In C / D: depressed conduction due to increased vagal activity (AV nodal block, bundle branch block)

C D

Vagal stimulation decreases the atrial force of contraction by marked shortening of action potential;

also increased K+ permeability & reduced Ca++ current both contribute to block AV conduction

Page 39: Antiarrhythmic drugs

3). Re - entry (circus movement tachycardia): if an ectopic beat finds one limb refractory

Impulse passes down

both limbs at equal speed

Retrograde Impulse will pass

When: the refractory period is shorter

than

the conduction time

or on recovery

it passes if the other side is slowly excited

esp. at AV node, Atrial or Ventricular Walls

Normal Damaged

Page 40: Antiarrhythmic drugs

C). Molecular & Genetic Basis of Arrhythmias

as in several congenital & acquired cardiac arrhythmias; there is either increased inward current

or

decreased outward current during the plateau,

Page 41: Antiarrhythmic drugs
Page 42: Antiarrhythmic drugs

Types of Arrhythmias

Page 43: Antiarrhythmic drugs

TACHYARRHYTHMIA

• Atrial– Supraventricular Tachycardia

• (Pulse Rapid, Regular, Ectopic Beats)

– Atrial Fibrillation• Ventricle

– Ventricular Tacharrhythmia– Ventricular Fibrillation

Page 44: Antiarrhythmic drugs

Brady-arrhythmias: ( rate < 60 beats/min.),

Tachy-arrhythmias: ( rate >100 beats/min.),

Page 45: Antiarrhythmic drugs
Page 46: Antiarrhythmic drugs

Sinus Bradycardia may be due to: hypothermia, hypothyroidism, cholestatic jaundice, raised intracranial pressure, β-blockers, digitalis etc., IHDs, sick sinus syndrome- fibrosis of the atrium & sinus node.

Heart Block • conduction block at any level in the conducting system; Prolongation of PR interval > 0.22 s & then gradually P waves don’t conduct. ( 1st – 3rd degree block ) • block lower than the Bundle of His produces Bundle Branch Block; widening of QRS complex up to 0.11 s ( N: < 0.10 s) .

Page 47: Antiarrhythmic drugs

Sick Sinus Syndrome sinus arrest & junctional escape beats (J). P waves are inverted in the cavity leads

Page 48: Antiarrhythmic drugs

Complete Heart Block

Congenital Complete Heart Block: QRS complex is narrow

with rate 52 beats/min.

Acquired Complete Heart Block: QRS complex is broad with rate 38 beats/min.

Page 49: Antiarrhythmic drugs

Tachy-arrhythmias: ( rate >100 beats/min.), may be due to Exercise, Emotion, Pain, Fever, Infection, Acute Myocardial Infarction, Acute Heart Failure, Acute Pulmonary Embolism, Hypovolemia, Pregnancy, Anemia, Hyperthyroidism, Pheochromocytoma, Excess Sympathetic or Reduced Parasympathetic Stimulation, etc.

Page 50: Antiarrhythmic drugs

Tachycardias are more symptomatic if the arrhythmia is fast & sustained

Supraventricular Tachycardia: Sinus Tachycardia, Atrial Fibrillation, Atrial Flutter, Ventricular Tachyarrhythmias: Ventricular Tachycardia, Ventricular Fibrillation, The Brugada syndrome, Torsades de pointes, Ventricular Premature Beats.

Page 51: Antiarrhythmic drugs

ECG (Ambulatory Record )

Supra Ventricular Tachycardia

Page 52: Antiarrhythmic drugs

Supra-Ventricular Tachycardiaat atrium or AV junction e.g.,

Atrial Premature Beats conducts to the ventricles with a slightly prolonged PR interval

Premature P waves are different from the sinus P waves

Page 53: Antiarrhythmic drugs

A prolonged QT interval

in

Supra-ventricular Tachycardia

Page 54: Antiarrhythmic drugs

P waves= Atrial rate is 150/min. R-waves=Ventricular rate is 75/min.

Atrial Tachycardia with IInd Degree AV. Block

Page 55: Antiarrhythmic drugs

F= flutter waves; flutter rate= 240/min.Every fourth F wave is transmitted to the ventricles;

Ventricular rate= 60/min.

Atrial Flutter

Page 56: Antiarrhythmic drugs

Atrial Fibrillation ( Irregular Rhythm Atrial Rate 300 To 600 /Min.)

Ventricular Rate Depends On Atrial Regularity At Av Node Entry

Page 57: Antiarrhythmic drugs

Atrioventricular Junctional Tachycardia

AV Nodal re-entry TachycardiaQRS complex are narrow & P waves not visible

Atrioventricular re-entry TachycardiaAfter narrow QRS complexes the tachycardia P waves are clearly seen.

During sinus rhythm of WPW Syndrome short PR interval & δ waves ( arrow )

Atrial Fibrillation in the WPW Syndrome.Tachycardia with broad QRS complexes with fast & irregular ventricular rate

Page 58: Antiarrhythmic drugs

Familial Atrial Fibrillation:

there is increased inward current of potassium

mutation of the gene for subunits of the slow delayed rectifier potassium

current,

Page 59: Antiarrhythmic drugs

Ventricular EctopicsVentricular Ectopics of different morphology

A pair of PVCs

Frequent PVCs

Following PVCs, non -sustained, a brief run of Ventricular Tachycardia

Page 60: Antiarrhythmic drugs

Ventricular Fibrillation( Post Myocardial Infarction )

Ventricular Ectopic followed by fibrillation

Page 61: Antiarrhythmic drugs

Torsade de pointes ( which is associated with syncope and sudden death ) decreased outward current of

Potassium due to: mutation in gene of potassium

channels leading to decreased repolarization & long QT subtypes 1, 2, 5 & 6.

Page 62: Antiarrhythmic drugs

Torsade de pointes

( a short lived atypical ventricular tachycardia which arises when ventricular repolarization is greatly prolonged - long QT syndrome: may be due to decreased K+, Mg+, Ca++ or drugs ) may be dangerous if resulting in ventricular fibrillation.

a brief period of idioventricular rhythm

Page 63: Antiarrhythmic drugs

The Brugada Syndrome:

( which is characterized by ventricular fibrillation & sudden

death ) increased outward current of Sodium due to: mutation in gene of sodium channels leading to congenital long QT subtype 3 syndrome

Page 64: Antiarrhythmic drugs

The Brugada Syndrome

( an inheritable condition )

Idiopathic Spontaneous Ventricular Fibrillation

with ST - Elevation in V1 – V3 Right Bundle Branch Block

Page 65: Antiarrhythmic drugs

Holter Recording: sudden increase in heart rate at 11:00 & 13:00 0 clock

Page 66: Antiarrhythmic drugs

Ambulatory ECG

ST depression with silent myocardial ischaemia

Page 67: Antiarrhythmic drugs

Treatment of arrhythmia

Page 68: Antiarrhythmic drugs

Why arrhythmias should be treated?

Arrhythmias may cause: Sudden Death, Stroke ( emboli )

Syncope, Heart Failure, Dizziness, Palpitation, or Asymptomatic at all.

because

Page 69: Antiarrhythmic drugs

Asymptomatic or

Minimally Symptomatic Arrhythmias

are usually not treated

because anti-arrhythmic drugs themselves can precipitate lethal arrhythmias;

Page 70: Antiarrhythmic drugs

Treatment of arrhythmias

is needed only if

• cardiac output is reduced, or if• some arrhythmias can precipitate serious / lethal rhythm disturbances e.g., ventricular fibrillations.

Page 71: Antiarrhythmic drugs

Cardiac Output is decreased

due to:

Increased rate of contraction

Decreased rate of contraction

Asynchronised rate of contraction

Page 72: Antiarrhythmic drugs

The major anti-arrhythmic mechanisms

1. Sodium Channel Blockade 2. Sympathetic Blockade at heart 3. Prolongation of Effective Refractory Period

4. Calcium Channel Blockade

Page 73: Antiarrhythmic drugs

Thanks for patience Listening

Page 74: Antiarrhythmic drugs

Anti-arrhythmic Drugs

Dr. Ashfaq Ahmad

Page 75: Antiarrhythmic drugs

1. DRUGS: ClassificationClass I ( Na Channel Blockers -Membrane-depressants ): Sub-Class

Ia: Disopyramide- Ventriculr DysrhymiaProcainamid - Paroxysmal atrial Fibrillation due to

Quinidin vagal overactivity

Ib: Lidocaine Tocainid Ventricular Tachycardia & Fibrillation Mexilitine immidiate after MIPhenytoin

Ic: Flecainide - Paroxysmal atrial Fibrillation

Propofenone - Recurrent Tacharrhythmias ( wolff Moricizine Parkin-son white syndrome)

Page 76: Antiarrhythmic drugs

Class II ( Beta Blockers ):AtenololMetoprololPropranololAcebutolEsmolol

Class III ( K+ Channels Blockers ) Prolong Action Potential

AmiodaroneSotalBretyliumIbutilideDofetil

Class IV ( Ca Channel Blockers )VerapamilDiltiazemBepridil

Page 77: Antiarrhythmic drugs

Class V ( Miscellaneous ): Adenosine Magnesium sulphate Digoxin Isoprenaline Atropine

2. Catheter Ablation:

3. Implantable Cardioversion Defibrillator ( ICD ):

Page 78: Antiarrhythmic drugs

Pharmacological Properties

Pharmacokinetics:

Bioavailability (>80%):

Digitalis, Quinidine, Ia drugs, Ib except Lidocaine, SotalolFirst-pass metabolism:

Lidocaine, Moricizine, Ic, Beta blockers

Page 79: Antiarrhythmic drugs

Routes of administration: Only Oral: Disopyramide, Acebutalol, Propofenone, Moricizine, Tocainide, Sotalol, Mexilitine, Flecainide.

Only Parenteral: Lidocaine, Esmolol, Ibutilide, Bretylium, Adenosine, MgSO4

Oral + Parenteral: Ia, Amiodarone, Propranolol, Ca-Blockers, Digitalis

Page 80: Antiarrhythmic drugs

Half-Life:

Short: Lidocaine (2hrs), Adenosine(<10 sec), Esmolol (10 min)

Long: Digoxin (36hrs), Phenytoin (<42hrs), Amiodarone (weeks).

Intermediate (4 - 20 hrs): All Others

Page 81: Antiarrhythmic drugs

Active Metabolites of: Quinidine, Procainamide, Propofenone, Adenosine

Page 82: Antiarrhythmic drugs

Mechanism of Action

Page 83: Antiarrhythmic drugs

Aim of the Treatment is

to make the depolarized tissues silent

Page 84: Antiarrhythmic drugs

- 85

influx

eflux

Absolute Refractory Period

Relative R.P.

E after depolarizationD

Threshold

Phase 0: Depolarization; Rapid Sodium Influx;Resting voltage has become positive.

Phase 1:Early Repolarization; brief K+ & Cl- eflux

Phase 2:Plateu phase; Ca++ influx

Phase 3:Rapid repolarization; K+ & Cl- eflux

Phase 4 ( automaticity ): Ratio of Na+/K+ permeability; cellularelectrolyte balance is slowly restored. Slow Diastolic Depolarization;Until the threshold potential is reached.

Early & Delayed - after depolarization may occur during relative refractory periodbefore the phase 4, due to myocardial damage, so leading to arrhythmias.

Early & Delayed depolarizations interrupt Phase 3

Page 85: Antiarrhythmic drugs
Page 86: Antiarrhythmic drugs

The anti-arrhythmic drugs:

a). Decrease: automaticity, Conduction,& Ecitability

The automaticity of ectopic sites more than at SA Node

by1) reducing the ratio of sodium & potassium

permeability so the membrane-potential during phase 4

stabilizes closer to potassium equilibrium at which K+ movement is stopped

2) or by

increasing the threshold ( making more positive ),

Page 87: Antiarrhythmic drugs

ii). the conduction & excitability of depolarized tissues

by reducing: excitatory currents to a level below for propagation,

due to decreased available ‘un blocked channels’

Page 88: Antiarrhythmic drugs

b). Increase: the refractory period more at

depolarized tissues than in normally polarized tissues by prolongation of recovery time of the channels

which are still able to reach the rested state thusextra-systoles are unable to propagate at all;

later impulses propagate more slowly and are subject to bidirectional block in re-entry arrhythmias.

Page 89: Antiarrhythmic drugs

Na Blockade (mainly):

Ia, Ib, Ic, Phenytoin, Amiodarone, Na Blockade (Some): Beta-blockers, Ca blockers

Page 90: Antiarrhythmic drugs
Page 91: Antiarrhythmic drugs
Page 92: Antiarrhythmic drugs

Beta-Blockade (Mainly):

Esmolol, PropranololBeta-Blockade (Some): Bretylium, Sotalol, Propofenone, Amiodarone (irreversible)

Page 93: Antiarrhythmic drugs
Page 94: Antiarrhythmic drugs

Beta Blockers, Na+ & Ca++ Blockers

Phase 4 slope decreased

Page 95: Antiarrhythmic drugs

K+ Channel Blockade:

Amiodarone, Sotalol, Bretylium, Ibutilide

Page 96: Antiarrhythmic drugs
Page 97: Antiarrhythmic drugs

K+ Blockers,Adenosine,Na+ Blockers

Increased duration of Action Potential

Page 98: Antiarrhythmic drugs

Ca-Blockade (mainly): Verapamil, Diltiazem Ca-Blockade (some): Amiodarone, Procainamide, Disopyramide, MgCl

Page 99: Antiarrhythmic drugs
Page 100: Antiarrhythmic drugs

Cardiac Effects

Page 101: Antiarrhythmic drugs

Pacemaker Activity Depressed (SA node/ Ectopic Sites): Ia (except Disopyramide),

Ib, Ic, II, III (except Ibutilide),

IV, Adenosine (No effect)

Action Potential (Prolonged duration): Ia, III

Page 102: Antiarrhythmic drugs

Refractory period Atrial / Ventricular (prolonged): Ia, Ib, II, III (except Bretylium) (some): Ic, IV AV Node (Prolonged): II, III, IV, Adenosine, AV Node (some): Ib, Ic, Bretylium, Ibutilide PR-Interval (Prolonged): II, III (except Bretylium, Ibutilide)

Page 103: Antiarrhythmic drugs

QRS Duration (Prolonged): Ia, Ib

QT Interval (Prolonged): Ia, III

Page 104: Antiarrhythmic drugs

Other Effects

Page 105: Antiarrhythmic drugs

Anti-muscarinic: Quinidine, Disopyramide

Cholinomimetic: Digitalis

Sympathomimetic: Bretylium

Page 106: Antiarrhythmic drugs

Alpha-blocking: Quinidine

Beta-blocking (Mainly): Esmolol, Propranolol, Sotalol, Bretylium

Some: Adenosine, Amiodarone, Quinidine, Procainamide, Ca-blockers

Ganglion blocking: Procainamide, Bretylium,

Page 107: Antiarrhythmic drugs

USES:

1. To relieve symptoms due to: • AV node re-entry tachycardia,• WPW syndrome,• Atrial fibrillation or flutter or • tachycardia. ( Class Ic or Class III ; Anticoagulants if needed, Catheter

Ablation )

Page 108: Antiarrhythmic drugs

2. To prevent sudden death in:• Life-threatening ventricular tachyarrhythmias, • Congenital long QT, • Ventricular Tachycardia.

( Beta-blockers +/- pacemaker, Calcium Channel Blockers, Catheter Ablation, or ICD )

Page 109: Antiarrhythmic drugs

3. Supra-ventricular (Only or mainly): IV, I, Adenosine (Some)

4. Ventricular (Only or Mainly): I, II, Bretylium

5. Both (equally): III (except Bretylium)

Page 110: Antiarrhythmic drugs

Adverse EffectsQuinidine: GIT, Cinchonism, Idiosyncracy

Procainamide: SLE, GIT, Allergic

Disopyramide: Atropine like

Lidocaine: CNS

Propofenone: Taste, constipation, Arrhythmias

Page 111: Antiarrhythmic drugs

Amiodarone: Vasodilatation, Accumulation in heart, liver, skin, tears

Bretylium: Ganglion blockade

Sotalol: Beta blockers like

Adenosine: Vasodilatation, Broncho-spasm, Heart Block

Page 112: Antiarrhythmic drugs

Contra Indications

CCF: Disopyramide, Flecainide, Beta blockersSA Node/AV node Dysfunction: Beta blockers, Ca Channel blockers, DigoxinMyocardial Infarction: FlecainideProlonged QT Interval:

Quinidine, Procainamide, Disopyramide, Sotalol, Bretylium, Amiodarone, Ibutilide

Page 113: Antiarrhythmic drugs

2. Catheter AblationThree or four electrode - catheters are placed into the heart chambers to record and pace from various sites.

Radio – frequency catheter ablation is frequently employed for symptomatic tachy – arrhythmias like:

AV re-entry tachycardia or with WPW syndrome: first line therapy to avoid the risk of sudden death .

Ventricular & Atrial Tachycardia ( in normal hearts ): easily cured by catheter ablation.

Page 114: Antiarrhythmic drugs

Atrial flutter:If not easily managed medically; 90 – 95 % effective.

Atrial fibrillation: After AV node ablation & pacemaker implantation a marked symptomatic improvement occurs but anticoagulants are still required. ( successful in 60 – 80 % cases )

Complications: Pulmonary vein stenosis, thrombosis, stroke.

Page 115: Antiarrhythmic drugs

X-Ray of a dual-chamber Implantable Cardioverter-defibrillator( IUD ) in a left pectoral position with atrial & ventricular leads

3.CARDIOVERTER DEFIBRILLATOR

Page 116: Antiarrhythmic drugs

Termination of ventricular fibrillationby the direct current shock after detecting it correctly

Electrogram recorded internally from the ventricular lead of an ICD shows chaotic ventricular activity consistent with ventricular fibrillation

The ICD recognizes ventricular tachycardia or fibrillation and automatically delivers pacing or a shock to the heart to cause

cardioversion to sinus rhythm

Page 117: Antiarrhythmic drugs
Page 118: Antiarrhythmic drugs
Page 119: Antiarrhythmic drugs

ECG – Body manifestation of

Depolarization and Repolarization Wavesof the Heart

Page 120: Antiarrhythmic drugs

Β - agonistsPacemaker potential (Phase 4)

Rapid depolarization

(Phase 0)

Plateau (Phase 2)

Repolarisation (Phase 3)

Class II

Class I

Class IV

Class III (and Ia)

Page 121: Antiarrhythmic drugs
Page 122: Antiarrhythmic drugs

The Conducting System of the Heart

Page 123: Antiarrhythmic drugs

PR Interval: Conduction Time From Atria to Ventricles

QRS Duration: Ventricular Conduction Time

QT Interval: Duration of Ventricular Action Potential

QRS Complex: Ventricular Depolarization

P – Wave: Atrial Depolarization

T – Wave: Ventricular Repolarization

Page 124: Antiarrhythmic drugs

Standard Leads (bipolar)

Augmented leads (augmented bipolar)

Chest Leads (uni-polar)

Page 125: Antiarrhythmic drugs
Page 126: Antiarrhythmic drugs

The

connections

& directions

of the

current flow

Page 127: Antiarrhythmic drugs

Cardiac Vectors: a). The hexaxial Reference System e.g., lead l is O0, lead ll is 600, lead lll is + 1200.

b). Direction of the vector: e.g., in lead lll positive & negative deflections are equal, so the mean QRS vector is perpendicular to lead lll